financetom
Business
financetom
/
Business
/
Mastek buys US-based BizAnalytica in boost for generative AI, global cloud capabilities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mastek buys US-based BizAnalytica in boost for generative AI, global cloud capabilities
Jul 19, 2023 9:17 AM

IT company Mastek Ltd on Wednesday (July 19) said it has acquired BizAnalytica, a premier data cloud and modernisation solutions provider headquartered in Boston, USA.

Share Market Live

NSE

The strategic acquisition will bolster Mastek's global data cloud services and generative AI capabilities and grant access to a talented pool of qualified data architects and scientists, according to a stock exchange filing.

Established in 2017, BizAnalytica offers end-to-end data cloud and modernisation solutions, including architectural design, system integration, data migration, automation, management, warehousing, and analytics. The company's expertise empowers enterprises to make intelligent, data-driven decisions that drive revenue growth.

A notable aspect of BizAnalytica's portfolio is its strategic partnerships with leading cloud platforms, such as Snowflake, Databricks, and AWS, further solidifying its position in the market, it said.

Hiral Chandrana, CEO of Mastek Group, said this acquisition marks a pivotal milestone in accelerating the company’s presence in data engineering, cloud services, and the rapidly-evolving generative AI domain.

BizAnalytica's strong data cloud and modernisation capabilities, along with its valuable partnerships with industry-leading cloud platforms, will enable us to decomplex the cloud transformation journey for our clients, delivering trust, value, and velocity, he said.

Lokesh Khosla, CTO and Co-Founder of BizAnalytica, said, "We firmly believe that Mastek is the ideal partner to reinforce our market-specific capabilities in data cloud and generative AI. This transition marks a turning point for BizAnalytica, and we eagerly anticipate collaborating with our joint customers in their transformation journey."

Shares of Mastek Ltd ended at Rs 2,177.00, up by Rs 24.15, or 1.12 percent on the BSE.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Nucor Insider Sold Shares Worth $1,303,712, According to a Recent SEC Filing
Nucor Insider Sold Shares Worth $1,303,712, According to a Recent SEC Filing
Jun 30, 2025
04:05 PM EDT, 06/30/2025 (MT Newswires) -- Kenneth Rex Query, Executive Vice President, on June 26, 2025, sold 10,000 shares in Nucor ( NUE ) for $1,303,712. Following the Form 4 filing with the SEC, Query has control over a total of 94,080 shares of the company, with 94,080 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/73309/000112760225018213/xslF345X05/form4.xml ...
Actuate Therapeutics Insider Bought Shares Worth $499,996, According to a Recent SEC Filing
Actuate Therapeutics Insider Bought Shares Worth $499,996, According to a Recent SEC Filing
Jun 30, 2025
04:07 PM EDT, 06/30/2025 (MT Newswires) -- Aaron G.L. Fletcher, 10% Owner, Director, on June 27, 2025, executed a purchase for 71,428 shares in Actuate Therapeutics ( ACTU ) for $499,996. Following the Form 4 filing with the SEC, Fletcher has control over a total of 10,196,456 shares of the company, with 10,196,456 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1652935/000110465925063991/xslF345X05/tm2519406-2_4seq1.xml ...
Actuate Therapeutics Insider Bought Shares Worth $499,996, According to a Recent SEC Filing
Actuate Therapeutics Insider Bought Shares Worth $499,996, According to a Recent SEC Filing
Jun 30, 2025
04:06 PM EDT, 06/30/2025 (MT Newswires) -- Leslie W. Kreis, 10% Owner, Director, on June 27, 2025, executed a purchase for 71,428 shares in Actuate Therapeutics ( ACTU ) for $499,996. Following the Form 4 filing with the SEC, Kreis has control over a total of 10,196,456 shares of the company, with 10,196,456 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1652935/000110465925063992/xslF345X05/tm2519406-3_4seq1.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved